MINIMUM bio


MINIMUM bio is dedicated to improving drug discovery processes by providing a versatile, high throughput platform based on phage display technology. Their mission is to rapidly identify proteins that bind to bioactive molecules, enabling the development of new therapeutic targets, drug modalities, and safer pharmaceuticals. They aim to reduce the time and cost of preclinical R&D and discover new drug modalities for more effective and safer drugs for everyone.

Industries

biopharma
biotechnology
test-and-measurement

Nr. of Employees

small (1-50)

MINIMUM bio

Sydney, New South Wales, Australia, Oceania


Products

Phage-display based target identification platform

A platform that constructs and screens phage-displayed protein libraries derived from cellular transcriptomes to identify binding partners of small molecules, biologics and molecular glues, with sequencing-based readout.


Services

Contract or collaborative services to identify cellular protein targets and off-targets of bioactive compounds by screening transcriptome-derived phage libraries and sequencing selected binders.

In-house R&D and partnered discovery programs to identify non-degrader molecular glues and their target/bait proteins using iterative phage-display screening.

Expertise Areas

  • Drug target identification
  • Phage display and library engineering
  • Chemical proteomics
  • Molecular glue discovery
  • Show More (2)

Key Technologies

  • Phage display
  • cDNA (transcriptome) library display
  • Phage biopanning (iterative affinity selection)
  • Sequencing-based readout of selected libraries
  • Show More (2)

News & Updates

Research Scientist – Molecular Biology at MINIMUM bio Pty Ltd, focusing on drug target discovery and new drug modalities.

This is a test post for the MINIMUM bio blog.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.